IN2012DN00359A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00359A
IN2012DN00359A IN359DEN2012A IN2012DN00359A IN 2012DN00359 A IN2012DN00359 A IN 2012DN00359A IN 359DEN2012 A IN359DEN2012 A IN 359DEN2012A IN 2012DN00359 A IN2012DN00359 A IN 2012DN00359A
Authority
IN
India
Prior art keywords
agent
omeprazole
antioxidant
directed
oral administration
Prior art date
Application number
Other languages
English (en)
Inventor
Juvonen Erik
Massimo Micolucci Louis
Original Assignee
Vetegen Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43465734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00359(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vetegen Llc filed Critical Vetegen Llc
Publication of IN2012DN00359A publication Critical patent/IN2012DN00359A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN359DEN2012 2009-07-20 2010-07-20 IN2012DN00359A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22689009P 2009-07-20 2009-07-20
PCT/US2010/042508 WO2011011351A2 (fr) 2009-07-20 2010-07-20 Formulation pharmaceutique stable d'oméprazole pour une administration orale

Publications (1)

Publication Number Publication Date
IN2012DN00359A true IN2012DN00359A (fr) 2015-05-22

Family

ID=43465734

Family Applications (1)

Application Number Title Priority Date Filing Date
IN359DEN2012 IN2012DN00359A (fr) 2009-07-20 2010-07-20

Country Status (11)

Country Link
US (1) US8530500B2 (fr)
EP (1) EP2456439A4 (fr)
JP (1) JP2012533633A (fr)
AU (1) AU2010276404A1 (fr)
CA (1) CA2768024A1 (fr)
CL (1) CL2012000169A1 (fr)
CO (1) CO6491061A2 (fr)
EC (1) ECSP12011618A (fr)
IN (1) IN2012DN00359A (fr)
PE (1) PE20120781A1 (fr)
WO (1) WO2011011351A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201402796SA (en) * 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
GB201306720D0 (en) 2013-04-12 2013-05-29 Special Products Ltd Formulation
WO2017145146A1 (fr) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprenant des inhibiteurs de la pompe à protons
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
GB2561355A (en) * 2017-04-10 2018-10-17 Eaststone Ltd Pharmaceutical composition and a method for manufacturing the same
CN107397719A (zh) * 2017-08-16 2017-11-28 洛阳市兽药厂 一种畜禽用奥美拉唑可溶性粉剂及其制备工艺
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
JP7515092B2 (ja) * 2017-10-18 2024-07-12 北海道公立大学法人 札幌医科大学 抗菌剤のスクリーニング方法
GB2585628A (en) * 2019-05-08 2021-01-20 Alkaloid Ad Pharmaceutical formulation
GB2616663A (en) * 2022-03-18 2023-09-20 Alkaloid Ad Skopje Pharmaceutical formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
BR0008403A (pt) * 1999-02-23 2002-01-29 Merck & Co Inc Formulação farmacêutica para administração oral
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AR045068A1 (es) 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
EP1742630A4 (fr) * 2004-04-16 2010-01-20 Santarus Inc Combinaison d'un inhibiteur de la pompe a protons, d'un agent tampon et d'un agent prokinetique
US8865692B2 (en) * 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation

Also Published As

Publication number Publication date
EP2456439A4 (fr) 2012-12-26
CO6491061A2 (es) 2012-07-31
US8530500B2 (en) 2013-09-10
EP2456439A2 (fr) 2012-05-30
CA2768024A1 (fr) 2011-01-27
CL2012000169A1 (es) 2012-08-31
US20110015233A1 (en) 2011-01-20
WO2011011351A3 (fr) 2011-05-19
ECSP12011618A (es) 2012-04-30
WO2011011351A2 (fr) 2011-01-27
PE20120781A1 (es) 2012-06-27
JP2012533633A (ja) 2012-12-27
AU2010276404A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
IN2012DN00359A (fr)
WO2009121039A3 (fr) Administration de compositions de benzodiazépine
WO2008085765A3 (fr) Formes dosifiées de petit volume de médicament contenant du sufentanil s'administrant par voie trans-muqueuse orale pour le traitement de la douleur
WO2009115178A3 (fr) Plaquette gingivale
MX2009011165A (es) Formulaciones farmaceuticas que contienen derivados del acido lipoico.
MX388963B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral
EA201290984A1 (ru) Гелеобразные фармацевтические композиции, препятствующие злоупотреблению
WO2012174158A3 (fr) Administration de benzodiazépine
ZA200800239B (en) Mucosal or enteral administration of biobogically active macromolecules
TN2012000392A1 (en) Oral formulations and lipophilic salts of methylnaltrexone
WO2011086093A3 (fr) Compositions pharmaceutiques pour l'administration orale de peptides de l'insuline
IL212734A0 (en) Pharmaceutical compositions comprising imidazoquinolin (amines) and derivatives thereof suitable for local administration
WO2009149056A3 (fr) Combinaisons de niacine et d'un oxicame
EP2258350A3 (fr) Forme de dosage cachant le goût comprenant du roflumilas
WO2010009140A3 (fr) Procédés, systèmes et dispositifs destinés à l'administration de dioxyde de chlore
WO2008046865A3 (fr) Système d'alimentation à long terme pour personnes agées
WO2014137797A3 (fr) Compositions stables d'activateur de glucokinase
MX2010005198A (es) Composiciones liquidas que comprenden valsartan.
EP2263637A4 (fr) Préparation médicinale pour administration orale
WO2011076840A3 (fr) Préparation aérosol pour bronchopneumopathie chronique obstructive
WO2009048940A3 (fr) Formulations pharmaceutiques de diacéréine
WO2010079433A3 (fr) Composition pharmaceutique qui comprend un inhibiteur de la dipeptidyl peptidase-iv
WO2010029093A3 (fr) Compositions destinées à une administration percutanée
HU0900482D0 (en) Pharmaceutical formulation for oral administration
WO2011017488A3 (fr) Combinaison d'un modulateur ppar-gamma sélectif et d'une incrétine pour le traitement du diabète et de l'obésité